Methylprednisolone Tablet

Phase 2/3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hand Injuries

Conditions

Hand Injuries, Finger Injuries

Trial Timeline

Sep 1, 2021 → Sep 1, 2023

NCT ID

NCT05003596

About Methylprednisolone Tablet

Methylprednisolone Tablet is a phase 2/3 stage product being developed by Johnson & Johnson for Hand Injuries. The current trial status is unknown. This product is registered under clinical trial identifier NCT05003596. Target conditions include Hand Injuries, Finger Injuries.

What happened to similar drugs?

1 of 10 similar drugs in Hand Injuries were approved

Approved (1) Terminated (2) Active (7)

✅clobetasol propionateGSK plcApproved

🔄Lebrikizumab + PlaceboEli LillyPhase 3

🔄Pimecrolimus Cream 1%NovartisPhase 3

🔄tocilizumab + saline solutionRochePhase 3

🔄dupilumab + PlaceboSanofiPhase 3

❌Ruxolitinib cream + VehicleIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05003596	Phase 2/3	UNKNOWN	Sep 1, 2021	Sep 1, 2023	Hand Injuries

Competing Products

17 competing products in Hand Injuries

See all competitors

Product	Company	Stage	Hype Score
Lebrikizumab + Placebo	Eli Lilly	Phase 3	44
ABT-981 + Placebo for ABT-981	AbbVie	Phase 2	35
Pimecrolimus Cream 1%	Novartis	Phase 3	40
tocilizumab + saline solution	Roche	Phase 3	40
denosumab + Placebo	Amgen	Phase 2	35
Dupilumab + Placebo	Sanofi	Phase 2	31
dupilumab + Placebo	Sanofi	Phase 3	40
clobetasol propionate	GSK plc	Approved	43
urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream)	Bayer	Phase 2	24
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
Ruxolitinib cream + Vehicle	Incyte	Phase 2	32
Ruxolitinib	Incyte	Phase 1/2	29
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream	Arcutis Biotherapeutics	Phase 1/2	26
alitretinoin	Basilea Pharmaceutica	Phase 3	34
alitretinoin	Basilea Pharmaceutica	Phase 3	34
alitretinoin	Basilea Pharmaceutica	Phase 3	34